ARMD and CNV patientinformation

Age Related Macular Degeneration (ARMD), Choroidal New Vessels (CNV) and Other CNV Disorder

ARMD is the most prevalent of the causes of choroidal new vessels (CNV). Because the abnormality affects the macula, it can cause severe vision loss. CNV from ARMD is affecting an increasing number of people as the average age of the world population increases, and is the most frequent cause of severe vision loss in people over 50 years of age.

Polypoidal Choroidal Vasculopathy: Our Local Variant of ARMD?

Although typical form of ARMD (drusen, CNV and its sequelae) is seen among the elderly in our population, choroidal bleeding and CNV occurs more frequently in another distinct clinical manifestation that has a differing characteristics when compared to ARMD. This variant of maculopathy is referred to as polypoidal choroidal vasculopathy (PCV).

Typically, PCV is associated with more leakages and subretinal bleeding, and other features of ARMD such as drusen or mottling of the RPE are absent. Another distinguishing characteristic is that, unlike features of ARMD which are usually present in both eyes in an individual with ARMD, the fellow eye in a patient with PCV often appears completely normal. There is typically absence of drusen in the eye with PCV.

ARMD is seen in individual above the age of 50. PCV often occurs in the population of the same age-group. However, in PCV, frequently patients in their 40s were also affected.

Picture of the right eye of an Asian patient with typical massive subretinal bleeding from polypoidal choroidal vasculopathy, presumable a variant of ARMD, seen much more frequently in our local Asian population. Note absence of drusen.

The Symptoms of ARMD

In mild cases, there may be little visual symptoms. However, with increasing disease severity the patient may notice distortion in vision or failing central vision. Reading or watching TV will be soon a difficulty, although the patient with ARMD can still navigate independent.

A dilated fundus examination by an Ophthalmologist is essential to make the diagnosis. Frequently, your eye doctor will order a test call fluorescein angiography to confirm the presence of a CNV complex, and to determine whether the lesion can be treated with laser treatment.

The mainstay of treatment is antiVEGF therapy, laser and photodynamic treatment. For cases that are not suitable for either of these treatments, surgical treatment may be required. Most surgical treatment options are considered “Investigational” at this stage, although good results have been reported in many patients.

Since March 2006, we used AntiVEGF as the first line treatment to patients with CNV due to AMD and other diseases. The three forms of AntiVEGF that are currently available are Ranibizumab (Lucentis/Accentrix®), Aflibercept (Eylea®) and Bevacizumab (Avastin®) intravitreal injections.

AntiVEGF had been shown to be efficacious both in improving vision and prevention of disease progression when given in a monthly intravitreal injection regime. In two large multicentre studies, (one comparing Ranibizumab to sham injection and another, a head to head comparison to PDT treatment), about 35% of patients gained 2 to 3 lines of vision(vs 11% in controls) and 95% of patients had stability in vision (vs 63% in control) when they received Ranibizumab intravitreal injections (the Phase III MARINA and ANCHOR trials, in publication). Ranibizumab (Lucentis®) received FDA approval on 30th June 2006.

A related AntiVEGF, Bevacizumab, is also used extensively in a similar manner although the drug was developed originally for colorectal cancer chemotherapy. The off-label use of Bevacizumab in the eye has been shown to be safe and efficacious in case series published previously. The push for Bevacizumab injection was primarily driven by the fact that Ranibizumab at that time was not available for clinical use (but results from phase II and III Ranibizumab trials were so encouraging that retinal specialists are compelled to try something similar while awaiting FDA approval for Ranibizumab) and that Bevacizumab is much cheaper as compared to Ranibizumab.

The effects are similar to Ranibizumab in a recent randomized control trials comparing Bevacizumab with Ranibizumab (CATT Study), although the 12- month results of the trial was ‘inconclusive’ when it comes to the safety profile of Bevacizumab. We await the 24-month results to see if the 2 drugs are similar in their efficacy and safety profile.

On November 18, 2011, The Food and Drug Administration approved aflibercept injection to treat wet age-related macular degeneration. Aflibercept can be injected up to every eight weeks, half as often as Ranibizumab. Less frequent dosing will potentially reduce the total number of annual injections for wet ARMD, doctor’s visits, and total healthcare bill while allowing wet ARMD patients to maintain vision that is comparable to the more frequent Ranibizumab injections. However, in real life, the actual number of injections, whether with Ranibizumb or Aflibercept, is quite similar with most patients requiring 6 to 8 injections per year to adequately control the Wet ARMD.

As of mid 2016, we had given more than 15,000 intravitreal injections, and our results mirrored the experience reported elsewhere. AntiVEGF injection is currently the treatment of choice for vast majority of patients with CNV, and this is sometimes used in combination with PDT treatment, especially if PCV disease is suspected.

In summary, patients with AMD/CNV and other disorders with CNV can now expect a greater likelihood in having an improvement in vision (which was marginal even with PDT (Verteporfin) monotherapy treatment previously), and also can expect virtually complete stabilization of vision when repeatedly treated with AntiVEGF such as Ranibizumab or Aflibercept. More research is currently ongoing to determine the effect of combination treatments (i.e. AntiVEGF with PDT) and new molecules on the durability and efficacy of such treatment.

(Note: From March 2016, Ranibizumab, which was previously marketed in Malaysia under the brand-name Lucentis® (Novartis), is changed to Accentrix® (Alcon Novartis). )

Role of Vitamins (antioxidants) in ARMD

In patients with extensive intermediate drusen, large drusen, non-central geographic atrophy, or advanced ARMD or vision loss due to ARMD in one eye, supplementary antioxidants plus zinc should be considered. The Age-related Eye Disease Study Group in 2001 had reported a one-third risk reduction with respect to development of severe ARMD in patients who took the supplements over a 6 year period. The formulation used in the study was: Vitamin C 500mg; Vitamin E 400 IU; beta carotene 15mg; Zinc (80mg of zinc oxide) and copper (2mg as cupric oxide).

Patients who are current smokers or previous smokers should not take this supplement as beta carotene may increase the risk of lung cancer or cardiovascular diseases in this group of patients.

What is known is that the natural history and treatment for PCV is not well established. This is an area of intense research. However, if there is demonstrable CNV on angiogram, the treatment options as used in CNV due to ARMD may be effective.

Thermal laser treatment is effective to treat CNV that is not too large, well defined, and located outside the macular region of the retina. This is a very effective treatment and has the advantage of being very economical. However, some patients may need recurrent treatment.

Age-related macular degeneration (AMD) is a deterioration or breakdown of the macula. The macula is a small area at the center of the retina in the back of the eye that allows us to see fine details clearly and perform activities such as reading and driving. In the wet form of AMD, abnormal blood vessels may grow in a layer beneath the retina, leaking fluid and blood and creating distortion or a large blind spot in the center of your vision.

Photodynamic therapy (PDT)–an outpatient procedure involving the use of a special light-activated drug–may be used to treat some patients with the wet form of AMD with fewer visual side effects than other treatments. The benefit of PDT is that it inhibits abnormal blood vessel leakage associated with wet macular degeneration, limiting damage to the overlying retina.

In PDT, the inactive form of the drug is usually injected into a vein in the arm, where it travels to and accumulates in abnormal blood vessels under the center of the macula. A special low-intensity laser light targeted at the retina activates the drug only in the affected area, damaging the abnormal blood vessels under the retina and leaving normal blood vessels intact.

Patients who are treated with PDT will become temporarily sensitive to bright light (photosensitive). Care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for several days.

PDT therapy is not effective for treatment of the dry form of AMD, caused by aging and thinning of the tissues of the macula.  While photodynamic therapy may preserve vision for many people, PDT may not stop vision loss in all patients. The abnormal blood vessels may regrow or begin to leak again. Every three months, a repeat examination including a fluorescein angiogram (a dye test) is required. Multiple PDT treatments may be necessary.

Massive subretinal blood may be drained surgically if warranted. In limited fresh subretinal bleeding, there are anecdotal reports that injection of a special medical grade gas into the eyeball followed by face-down posturing (as much as possible, day and night) for a week can displace the blood from the macular, thus limiting scarring response and vision loss.

Screening

Any patient who is at risk for ARMD should have an eye examination at least once a year. Patient with dry ARMD may also undertake daily self screening with an Amsler Grid, which is a simple card with grid boxes printed and readily available from their eye doctors.